Please Accept Our Sincere Apologies
Our company, its research, and our intellectual property is self-funded by stakeholders and from profits derived from our urologic services. We are a small group of doctors, scientists, and clinicians with just one focus: developing a cure for Peyronie's disease.
Unfortunately, there's much more to it when it comes to actually delivering breakthrough technology to patients and getting those services covered by insurance. Our hands will be tied for at least another twelve months as we create enough added value through new drug patents for our future Pharma partner to fund the $50 million costs that will be associated with getting all clearances, universal insurance coverages, and worldwide distribution for all of our breakthroughs.
If you're a patient or clinician who's reached out wanting additional information on our breakthroughs to date, we sincerely apologize for our inability to be responsive. Like many early stage Biomed enterprises, we're somewhat understaffed, overworked, underpaid, and legally limited in terms of what we can share publicly at this moment.
Apology to Clinicians: We are currently navigating the creation of new drugs in tandem with our novel drug delivery system and patient protocols. Unfortunately at this point, we cannot share anything about what we're doing with anyone, and we can't make our technologies available for testing yet. Nor can we publish our exciting insights and outcomes in clinical journals.
All the pieces are intertwined with the patents, which are key for us getting funding to make all this universally available. We've been advised this "lock up" period will likely come to an end within the next twelve to eighteen months. We're on pins and needles waiting to help you better serve Peyronie's patients.
Apology to Peyronie's Patients: We are working around the clock to deliver on our curative vision for one reason: to help the growing number of men who are so horribly afflicted by Peyronie's Disease. Unfortunately, our hands will be tied for another 12-18 months as we create added value to attract the $50 million in costs required for all the clearances, universal insurance coverages, and technology distribution.
When it comes to patients, possibly the three most heartbreaking parts of what we do are:
- Seeing men fall for the endless array of fraudulent Peyronie's Disease "cures". Right now, P-shot derivatives and the endless array of acoustic wave therapies are most likely the worst offenders—borderline criminal, in our opinion. Over the past 20 years, we have seen a great deal more of them.
- Witnessing well-meaning patients and even healthcare professionals provide Peyronie's patients incorrect advice, usually via online forums. We're not allowed to interject and provide better guidance, which is difficult at times given all we now understand about the uniqueness of each Peyronie's case.
- Reading heartbreaking posts on the vulnerable mental and physical states of so many men with Peyronie's disease. Some of these have been prominently displayed in our lab as a constant reminder of the significance of everyone's work.
Our institute is focused on finding a cure for Peyronie’s Disease.
- We unlocked the underlying epidemiology of Peyronie's Disease.
- Our research uncovered six "Peyronie's Accelerators", and in order to successfully heal this disease, they must be controlled and optimized. Along with the scope and size of fibrous plaques, these factors are usually the root cause of why some men succeed with certain therapeutics while others do not.
- Our patented therapeutics combining pulsated gas injections just before injection of intralesional drugs opens small pathways for medicines to become effective, which breaks down Peyronie's fibrosis without surgery.
- The factors of a Peyronie's case, including plaque size, density, and position, as well as the state of each Peyronie's Accelerator and a calculated health factor rating, are all taken into consideration by our unique therapeutic algorithm. Continued refinements to this algorithm will be crucial for rapid training of urologists around the globe in the future.
- Earlier in the development of our Peyronie's technology, we sometimes couldn't get the penis back to its original size after removing Peyronie's plaques. Thus, we developed novel methods for cosmetic urology (penis augmentation). Since then, we uncovered the secret to regaining lost size from Peyronie's Disease during our therapeutic treatments. However, our platform for cosmetic urology—headed by renowned reconstructive urologist Kenneth J. Carney, MD, PHARM, FACS—has enjoyed notable success. A primary source of funding for our Peyronie's cure research has come from our cosmetic urology platform.
- We are currently developing technologies that will leverage improved treatment methods and novel drugs to expedite the progression of obstinate Peyronie's cases. We've started talks to collaborate with a global pharmaceutical company to finance our FDA approvals and make sure the revolutionary ExoSurge technology becomes available globally in the upcoming years.
We are developing novel approaches to Peyronie's disease care including non-surgical solutions that break down fibrous plaques and scar tissue. Our patented pulsating gas injections are able to reach deeply into fibrous plaques, opening small pathways for injectable medications to effectively reach deep into dense Peyronie's fibrosis. As a consequence, after several treatments, plaques begin to dissolve.
Unlike current Peyronie's surgical and non-surgical approaches that only treat symptoms like erect penile curvature, ExoSurge holds the promise to achieve optimal and long-lasting disease control through the management of quantifiable "Peyronie's Accelerators" and
our inter-fibrous gas injections to remove penile fibrous plaques.
Peyronie’s is a wickedly challenging disease to completely resolve. It's been medically identified for over six centuries (long before "Peyronie" added his name to the disease) and the only treatments to date address symptoms. Curative Peyronie's care requires a three-pronged approach for success, including:
- ExoSurge is a curative therapeutic treatment that includes a novel drug delivery Medtech device where injected pulsated gas destalizises fibrous Peyronie's plaques enough where injected intralesional drugs can slowly dissolve Peyronie's fibrosis. We've succeeded removing fibrous plaques using generic drugs but we're experimenting with new medicines that will hopefully speed up the plaque dissolution processs.
- ExoSurge is a detailed protocol customized based upon a wide variety of variations in patient disease factors and personal health dynamics. These factors are crucial to include in the treatment plan for every Peyronie's case to ensure fibrotic removal.
- ExoSurge requires patient management and patient responsibility managing discovered metrics we call “Peyronie’s Accelerators”. If these metrics remain elevated during treatments, improvement is severely compromised.
Better Science, Better Medicines
ExoSurge inter-fibrous gas injections are a key aspect to providing a curative outcome for Peyronie's Disease. Unlike current Peyronie's treatments and surgeries that only attempt to address symptoms of Peyronie's disease through surgical straightening, traction, or treatments, ExoSurge technology breaks up and removes the fibrous tissue that's the underlying cause of debilitating Peyronie's symptoms such as erect curvature, penile pain, lost length, and shaft misshapenness.
New, Important Peyronie's Insights
ExoSurge can immediately be deployed during the acute phase of the disease preventing the growth of the fibrous plaques that cause a Peyronie's diagnosis and provide long-lasting disease control. Thus, in cases born from acute penile trauma, urologists will be able to arrest fibrotic growth before it happens.
Our research indicates over 40% of men have "asymptomatic Peyronie's". They have bits, pieces, or diffuse fibrosis within the soft tissue of the penis from minor injuries but exhibit no obvious symptoms.
Our research indicates the majority of severe-symptom Peyronie's cases (65%) are born from a series of life-long micro traumas to the penis organ going back to men's childhoods. When patients encounter one or more of our newly discovered "Peyrnoie's Accelerators" their case becomes symptomatic and if those Accelerators are not properly managed, the growth of penile fibrosis can become rapid and severe. Every man who lives long enough will face one or more the Peyronie's Accelerators, but they can be triggered at any age. Our analysis shows about 25% of severe-symptom Peyronie's cases where caused by a memorable, acute trauma to the penis organ, and the final 10% of cases are causes by other circumstances and conditions, with healthcare related penile injury being the most common source in this last group.
We plan to begin prospective clinical trials in 2026 and will subsequently file for FDA approval for our gas and drug injections in the treatment Peyronie's Disease. We believe and it is our goal that this curative Peyronie's technology will be 100% covered by traditional health insurance including medicare. Our devices, drugs, case management algorithm, and decalcification module are not yet available for sale.
If you are a urologic clinician with potential interest with participating in our upcoming prospective clinical trials, please click here.
If you are a Peyronie’s patient and would like to potentially participate in our upcoming prospective national clinical trials, please click here.
We are science-driven and led by executives and medical advisors. Let us show you our plans to revolutionize the treatment of Peyronie’s disease.
For Clinicians
ExoSurge® technology is science-driven, supported by extensive in-clinic use and ongoing clinical research.
We invested over twenty years and $20 million unearthing the etiology and extracellular matrix behind every aspect of Peyronie's Disease manifestation. We understand that your reputation is at stake when you choose to partner with a new technology and that safety and efficacy are paramount to you.
The ExoSurge® Inter-fibrinous Pulsated Gas and Drug Technology (IPG) is the first and only technology of its kind specially engineered to permanently remove the penile fibrosis and Peyronie's plaques that trigger a Peyronie's diagnosis – and it does so safely and without collateral tissue damage.
With high patient satisfaction for a conservative procedure, ExoSurge® represents a new way to treat Peyronie's, whether it be from long established penile fibrosis or calcified plaques, active phase penile injury patients, symptoms of early stage Peyronie's such as diffuse penile fibrosis, or preventative care for patients without symptoms but with measurable penile fibrosis that shows up on ultrasound.
To learn more about about how we believe ExoSurge® IPG is positioned to revolutionize Peyronie's Disease care, click below.
We are completely dedicated to developing a cure for Peyronie's disease.
Our goal is to eliminate the fibrous plaques that produce the numerous symptoms that Peyronie's is known for, along with the fibrous plaques themselves, using non-surgical treatment technologies, intralesional drugs, and supporting diagnostics.
Our vision is for urologists worldwide to have easy access to our turn-key technology and for health insurance to pay for most or all of the cost of this treatment.
ExoSurge® is the world's first clinically-proven treatment to conservatively and permanently remove plaques and fibrosis associated with a Peyronie's diagnosis.
What do ExoSurge® patients say about our Peyronie's technology?
The following are verified patient reviews. Our clinic has supporting documentation. Edits have occasionally been made to correct grammatical or spelling errors.
To learn more about our diagnostics and Peyronie's treatments with ExoSurge technology right away, please visit our clinical website and schedule a "one on one" phone consultation or a visit to our clinic in the Buckhead area of Atlanta, Georgia.
Stay Up To Date
If you are a Peyronie's patient who has interest in participating in one of our upcoming clinical trials around the United States, please click here
If you are a urologic clinician who has a potential interest with being involved in our upcoming prospective clinical trials, please click here
If you would like to stay abreast of our progress during clinical trials and in the future, please click here:
Sign up to follow our story and to watch us grow!